ARA-290 (Cibinetide): A Research Overview of the Innate Repair Receptor Agonist

ARA-290 stands somewhat apart from most of the compounds discussed in peptide research circles. It was not repurposed from a fitness or cosmetic context — it was deliberately engineered by a pharmaceutical company as a drug candidate, advanced through human Phase II trials, and granted orphan-drug status by regulators. That gives it a more developed clinical record than most research peptides. It also makes the distinction between “investigated” and “approved” especially important to get right, because the two are easy to conflate and frequently are.

This overview summarizes what the published literature reports on ARA-290’s origin, mechanism, clinical evidence, and precise regulatory status. Throughout, it describes what studies observed in their study populations. It is not dosing guidance, medical advice, or a recommendation for use.

What ARA-290 Is

ARA-290, also known by the international nonproprietary name cibinetide, is a synthetic 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin (EPO). The design goal was specific and clever: retain EPO’s tissue-protective, anti-inflammatory activity while eliminating its effect on red blood cell production. It was developed by Araim Pharmaceuticals around its discovery of the innate repair receptor (ARA-290 / IRR mechanism, PMC).

That EPO origin without the erythropoietic effect is the single most important thing to understand about ARA-290, and a common point of confusion. Native EPO raises hematocrit, which carries cardiovascular and clotting risks. ARA-290 was engineered specifically not to do that — it does not stimulate red blood cell production. Expecting EPO-like blood effects from it reflects a misunderstanding of its design.

Mechanism of Action

ARA-290 acts on the innate repair receptor (IRR), a heteromeric complex formed by the erythropoietin receptor (EPOR) together with the beta-common receptor (CD131). A key feature of this receptor is that it is selectively upregulated in injured or inflamed tissue and is largely absent from healthy, uninjured cells (IRR receptor biology, PMC). That selectivity is part of the appeal as a research target: the receptor the molecule engages tends to appear where there is damage to repair.

Once bound, IRR activation is reported to initiate a local anti-inflammatory response, suppress pro-inflammatory cytokine signaling, inhibit cell death (anti-apoptotic) pathways, and promote tissue repair processes, including neurite outgrowth. Studies in animals lacking the beta-common receptor show no behavioral effect of ARA-290, implicating that receptor as its site of action (mechanism and knockout evidence, PMC). A separate line of work has reported that ARA-290 also antagonizes the TRPV1 channel, which may contribute to its analgesic effects through a distinct route (ARA-290 and TRPV1, ScienceDirect).

The Clinical Evidence Base

This is where ARA-290 genuinely differs from most research peptides: there is real, peer-reviewed human trial data, not only animal work. It should still be read carefully, because the trials are early-phase and small.

Type 2 diabetes and neuropathy. A Phase II study published in a peer-reviewed journal enrolled patients with type 2 diabetes and painful neuropathy, who self-administered 4 mg of ARA-290 or placebo subcutaneously daily for 28 days. The report noted no identified safety issues and described improvements in HbA1c and lipid profiles over the observation period (ARA 290 Phase II in type 2 diabetes, PubMed).

Sarcoidosis small-fiber neuropathy. ARA-290 has been studied most extensively in sarcoidosis-associated small-fiber neuropathy. Randomized, placebo-controlled work in this setting reported increased corneal nerve fiber density — an objective measure of small-nerve-fiber abundance — alongside reduced neuropathic pain scores (clinical evidence summary).

The honest limitations matter as much as the findings. The trials were small and largely single-institution; the diabetes study was underpowered for its metabolic secondary endpoints, and no Phase III multicenter trial was completed. Preclinical work is broad — spanning models of myocardial infarction, shock, and other injuries — but the breadth of animal data is not the same as confirmed human efficacy. ARA-290 is best described as promising and investigational, with encouraging early human signals that were never carried to a confirmatory trial.

Regulatory Status — Read This Carefully

The status below reflects 2026 and may change; verify against current sources before relying on it. ARA-290 is not FDA-approved for any human indication. What it does hold is FDA Orphan Drug Designation — granted to Araim Pharmaceuticals in 2016 for sarcoidosis — along with Fast Track designation for neuropathic pain in sarcoidosis (FDA orphan drug designation announcement, PR Newswire).

Here is the distinction that is most often blurred, and it is worth stating bluntly: orphan-drug designation is not approval. It is a status that grants development incentives — such as a period of marketing exclusivity, tax credits, and fee waivers — to encourage the development of treatments for rare diseases. It says nothing about whether a drug has been shown to be safe and effective. A compound can hold orphan designation for years and never be approved.

That is essentially what happened here. No New Drug Application was filed, and following Araim Pharmaceuticals’ closure, no sponsor holds an active investigational application for ARA-290 in the United States. Without a new sponsor restarting development, there is no current pathway to approval (2026 development and regulatory status). Separately, ARA-290 is prohibited by the World Anti-Doping Agency for competing athletes, owing to its tissue-repair activity (anti-doping status note).

Why ARA-290 Draws Research Interest

The appeal is well-defined. ARA-290 represents a rational, engineered approach to a specific problem — capturing erythropoietin’s repair signaling while leaving its blood-cell effects behind — acting on a receptor that appears chiefly at sites of injury, with a mechanism mapped in detail and genuine, if early, human data behind it. For researchers in neuropathy, inflammation, and tissue protection, it is among the more clinically substantiated compounds in this space. The accurate summary is mechanistically elegant, supported by early-phase human trials, never confirmed in Phase III, not approved, and currently without an active development sponsor.

For deeper reading, the primary literature cited throughout this article is the best starting point. Related tissue-protection and neuro-inflammation topics are collected in our peptide research library, which gathers reference material on the wider class of compounds discussed here.